Retatrutide is a novel triple-receptor agonist targeting glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors. This randomized controlled trial, published in The New England Journal of Medicine, investigates its effectiveness in treating obesity among adults who do not have diabetes.
The study involved 2,339 participants who were assigned to receive either retatrutide (at doses of 4 mg, 9 mg, or 12 mg) or a placebo for a duration of 80 weeks. The primary outcomes measured included the percent change in body weight, changes in the WOMAC pain score for participants with knee osteoarthritis, and alterations in the apnea-hypopnea index for those with obstructive sleep apnea.
Results indicated that participants receiving retatrutide experienced significant weight loss, with an average percent change in body weight of -17.6% for the 4 mg group and -23.7% for the 9 mg group. The trial also aimed to assess the impact of retatrutide on pain and sleep apnea, although specific outcomes for these measures were not detailed in the abstract.
This study’s design, being a phase 3 randomized controlled trial, provides a robust framework for evaluating the efficacy of retatrutide in a diverse population. However, the exact mechanisms by which retatrutide influences weight loss and its broader implications for health outcomes require further exploration.
What this study does not show
While the study demonstrates significant weight loss associated with retatrutide, it does not establish long-term safety or efficacy beyond the 80-week trial period.
Evidence scorecard
- Analytic validity: Established
- Clinical validity: Established
- Clinical utility: Established
This evidence is derived from a human randomized controlled trial.